Navigation Links
AviaraDx Announces CAP Accreditation of Its Laboratory Operations
Date:10/1/2007

CARLSBAD, Calif., Oct. 1 /PRNewswire/ -- AviaraDx announced today that the company's Carlsbad, CA, CLIA laboratory operation has received its College of American Pathology (CAP) accreditation. The laboratory offers two new molecular oncology tests to hospitals and physicians across the United States.

CancerTYPE ID(TM) is a 92-gene expression assay capable of classifying 39 tumor types.

CancerTYPE ID(TM) provides a molecular classification of metastatic cancer and guides the physician in differential diagnosis and identification of the primary tumor site. When used early in the cancer classification process, CancerTYPE ID is a powerful tool to quickly determine the likely primary tumor site, focusing the selection of confirmatory immunohistological and imaging procedures.

AviaraDx' H/I(TM) (HOXB13/IL17BR) test is a molecular extension of estrogen receptor (ER) testing and represents a significant improvement when assessing a patient's risk of breast cancer recurrence and the likely benefit from endocrine therapy. The H/I(TM) test is used to stratify ER+, node-negative breast cancer patient into high and low risk of recurrence as well as to predict response to endocrine therapy. Both HOXB13 and IL17BR biomarkers are controlled by estrogen and provide novel information about estrogen signaling in ER+ breast cancer.

The AviaraDx CLIA laboratory enables clinical and research laboratories, physicians, and pharmaceutical companies to incorporate these innovative molecular oncology tests into clinical practice. "We are very excited about receiving CAP accreditation, ensuring that our new molecular oncology tests meet the highest quality standards in the clinical laboratory industry", stated Antonius Schuh, Ph.D., CEO of AviaraDx. "Our mission is to continue to bring novel molecular oncology assays to physicians and patients, which answer unmet clinical needs in cancer care."

About AviaraDx

AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will eventually provide information critical to predict treatment response to a given therapeutic regimen.

AviaraDx offers diagnostic tests to qualified physicians or laboratories through its certified CLIA laboratory service operations. The company's first diagnostic test offerings are based on its proprietary technologies used in molecular classification of metastatic cancer, CancerTYPE ID(TM), and its H/I(TM) (HOXB13/IL17BR) test to assess risk of recurrence and response to endocrine therapy in certain breast cancer patients.

CONTACT:

Antonius Schuh, Ph.D.

Chief Executive Officer of AviaraDx, Inc.

+1 (760) 579 0500

aschuh@aviaradx.com


'/>"/>
SOURCE AviaraDx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
Breaking Biology Technology:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):